Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

gamma-Aminobutyric acid (GABA) agonists have been proposed for the treatment of tardive dyskinesia, but their therapeutic potential has been limited by side effects and toxicity. To elucidate further the role of GABA in neuroleptic-induced dyskinesias, we evaluated tetrahydroisoxazolopyridinol (THIP), a new, less toxic GABA analog and GABA receptor agonist, in both a dose-finding (single-dose) pilot study with five patients and a longer (four-week) placebo-controlled study with 13 patients. The patients were videotaped during a standardized examination; tardive dyskinesia, parkinsonian symptoms, and eye-blinking rates were rated blindly and randomly. The maximal short-term dose of THIP was 10 to 25 mg, whereas in the longer-term study the highest daily dose ranged from 20 to 120 mg. Tardive dyskinesia was unchanged during THIP treatment, but preexisting parkinsonism increased significantly and eye-blinking rates decreased. Psychiatric symptoms showed no significant changes, although tension and depression lessened. Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks. Although THIP is not an effective new treatment for tardive dyskinesia, more specific GABA agonists should be evaluated in future studies of this syndrome.
 ...
PMID:The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. 612 70

Psychiatric symptoms and psychometric variables were assessed in thirty three female inpatients with anorexia nervosa. Our sample was a relatively "severe" group. All of the patients were still in treatment at the time of the study and had fulfilled the strict diagnostic criteria clearly defined by Crisp, Bruch, Russell, Dally and Gomez. Since the initial descriptions of anorexia nervosa were made, there has been a great confusion about whether it is a homogeneous illness or not. Our findings bear consistently with the clinical observation that there are distinct diagnostic sub-groups within the anorexia nervosa syndrome. Objective psychological measures lend support to the clinical evaluation that neurotic mechanisms (hysterical, phobic or obsessionnal features) are unusual in anorexia nervosa. Within the primary anorectics, the major clinical predictors of a poor outcome were: age (greater than 20 years), persistant amenorrhea and importance of weight loss. Within the 33 patients, the other predictors of a poor outcome were: small weight gain during treatment, absence of manifest distress (denial or satisfaction) and bulimia associated with self-induced vomiting. On the other hand, anxiety, depression and premorbid personality traits were not systematically associated with a poor prognosis. The population studied was heterogeneous in terms of MMPI profiles and Rorschach scores. The extent to which all our patients deviated from the norm on the Rorschach scores was not negligeable. The Rorschach variables linked to a clinical severity were the percentage of responses F (Form) and F + (form quality). The combination of these scores with the MMPI Anxiety Index (WELSH) lead to identify different sub-groups with a poor prognosis. According to H. Bruch theories, cognitive and perceptual difficulties, disturbance of body image of internal sensations as well as deficiency in identifying emotional states were very common. Rorschach responses of anorectic patients were compared with those of schizophrenic and depressed control groups of F% and F + % mean scores. The results showed that the anorectic group was closer to the schizophrenic group than to the depressed one.
 ...
PMID:[Anorexia nervosa. A clinical and psychometric study]. 665 Oct 83

N-methyl-D-aspartate receptor (NMDA) encephalitis is a recently described autoimmune disease that typically presents with prodromal symptoms including upper respiratory tract infection, headache, fever, nausea, vomiting and diarrhea. Psychiatric symptoms follow within weeks, including anxiety, insomnia, mania, paranoia and grandiose delusions. The diagnosis is confirmed by the detection of NMDA antibodies in the serum or cerebrospinal fluid (CSF).1 Tumours, especially teratomas, are frequently associated with NMDA encephalitis; however, only 5% of male patients older than 18 years have been found to have an underlying tumour. Optic neuropathy associated with NMDA encephalitis is being increasingly recognised in the literature2-6 and was reviewed most recently by Mugavin et al.2 in 2017. In this report, we present a case of bilateral optic neuropathy in a young man diagnosed with NMDA receptor encephalitis.
 ...
PMID:Optic Nerve Atrophy in N-methyl-D-aspartate (NMDA) Encephalitis. 3172 24